Brain metastases (BM) from non-small cell lung cancer (NSCLC) significantly contribute to poor prognosis, with their progression intrinsically linked to the unique immune microenvironment of the brain. This review comprehensively examines the dual regulatory roles and underlying mechanisms of three pivotal cell types within the metastatic niche-tumor-associated macrophages (TAMs), microglia, and astrocytes-during brain metastasis development. TAMs promote tumor invasion and the establishment of an immunosuppressive milieu through metabolic regulation and differentiation into functional subtypes, with profiles distinct from those in primary tumors. As resident immune cells of the central nervous system, microglia show marked functional polarization: they can inhibit metastasis by directly targeting tumor cells, cooperating with adaptive immunity, and enhancing radiosensitivity. However, under specific microenvironmental cues, they may also support tumor growth and immune evasion. Similarly, astrocytes transition from a neuroprotective to a tumor-promoting phenotype, driving progression through inflammatory cytokine secretion, gap junction-mediated intercellular communication, metabolic reprogramming, and exosomal signaling. Building on these mechanistic insights, this review further summarizes emerging therapeutic strategies targeting these cell types, including engineered vesicle-mediated TAM reprogramming, nanoparticle-based combination therapies, metabolic checkpoint interventions, and targeted signaling pathway inhibitors. These insights advance the "seed and soil" hypothesis in brain metastasis and support the development of precision therapies targeting the microenvironment to improve outcomes for patients with NSCLC and BM.
Glioblastoma (GBM) is a highly aggressive brain tumor with a complex tumor microenvironment (TME) that includes immune cell infiltration, notably macrophages. The role of macrophages in GBM progression is influenced by their polarization state, which can be either pro-inflammatory (M1) or immunosuppressive (M2). This study investigates the macrophage polarization in GBM, identifying key macrophage-related genes and their impact on tumor progression. Analysis of TCGA-GBM data revealed that macrophage infiltration correlates with poor prognosis, with 41 risk-associated genes identified. DSP dataset analysis highlighted 378 differentially expressed genes between CD68+ macrophages and GFAP+ controls, including immune-related genes like SPP1, CD74, and C3. Cross-validation with single-cell RNA-seq confirmed the expression of 9 key genes, with 7 genes being macrophage-specific. In vitro experiments using conditioned media from GBM cell lines demonstrated that GBM cells promote macrophage polarization towards an M2-like phenotype. Overexpression of CD74, CLEC7A, and IFI30 in macrophages further enhanced M2 polarization, which was associated with increased tumor-promoting functions, including enhanced invasion and reduced apoptosis in GBM cells. Together, these findings highlight the role of M2 macrophage polarization in promoting GBM progression and suggest that targeting macrophage polarization pathways may offer therapeutic potential.
Pancreatic ductal adenocarcinoma is a malignancy characterized by profound immunosuppression and universal resistance to immunotherapy. The complex tumor microenvironment is a critical determinant of therapeutic failure. The chemokine C-X-C motif chemokine ligand 11 (CXCL11) exerts dual immunomodulatory roles in various tumors; however, its expression pattern, clinical significance, and molecular mechanisms in pancreatic cancer remain unclear. This study integrated clinical cohort analysis, tissue microarray, transcriptomic sequencing, and in vitro functional experiments. Immunohistochemistry and multiplex immunofluorescence were used to analyze CXCL11 expression and its spatial relationship with immune cell infiltration. Transcriptomic sequencing was performed to identify differentially expressed genes after CXCL11 knockdown, followed by pathway enrichment analysis. CXCL11 knockdown and overexpression models were established in Panc02 and SW1990 cell lines, and western blotting was used to verify the regulatory effects on the nuclear factor kappa-B (NF-κB) signaling pathway and downstream CC motif chemokine ligand 2 (CCL2) expression. CXCL11 expression was higher in paratumor tissues than in tumor tissues of pancreatic cancer, and its high expression was significantly associated with shortened overall survival and more aggressive pathological features. Co-enrichement of CXCL11 with immunosuppressive markers such as CD163, CD11b, and programmed death-ligand 1 in paratumoral regions suggests its involvement in forming a spatially heterogeneous immunosuppressive barrier. Tissue-level analysis revealed a significant positive correlation between CXCL11 expression and the M2 macrophage marker CD163, as well as the myeloid-derived suppressor cell marker CD11b. Transcriptomic and functional experiments confirmed that CXCL11 activates the NF-κB signaling pathway and upregulates CCL2 expression. Tissue microarray further validated their positive correlations at the protein level. CXCL11 plays a pro-tumorigenic role in pancreatic cancer, with high expression levels predicting poor prognosis. By activating the NF-κB signaling pathway to upregulate CCL2, CXCL11 drives the "CXCL11-NF-κB-CCL2″ signaling axis, which, together with its enrichment in paratumoral regions, promotes the recruitment and activation of immunosuppressive cells and forms a functional immunosuppressive barrier at the invasive front. This provides a mechanistic explanation for immunotherapeutic resistance in pancreatic cancer and suggests CXCL11 and its related pathways as potential therapeutic targets.